Citadel Advisors
CABA icon

Citadel Advisors’s Cabaletta Bio CABA Stock Holding History

Citadel Advisors’s Portfolio CABA Stock Details CABA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$11M Buy
+3,522,112
New +$11.6M ﹤0.01% 3435
2026
Q1 		– Sell
-33,502
Closed -$93K – 13060
2025
Q4 		$73.4K Sell
33,502
-671,963
-95% -$1.67M ﹤0.01% 11848
2025
Q3 		$1.65M Sell
705,465
-982,515
-58% -$1.69M ﹤0.01% 6463
2025
Q2 		$2.57M Buy
1,687,980
+1,687,630
+482,180% +$2.63M ﹤0.01% 5254
2025
Q1 		$485 Buy
+350
New +$746 ﹤0.01% 14255
2024
Q4 		– Sell
-4,511
Closed -$15.8K – 14560
2024
Q3 		$21.3K Sell
4,511
-315,035
-99% -$1.82M ﹤0.01% 12731
2024
Q2 		$2.39M Buy
319,546
+317,305
+14,159% +$3.89M ﹤0.01% 4985
2024
Q1 		$38.2K Sell
2,241
-31,639
-93% -$679K ﹤0.01% 12444
2023
Q4 		$769K Buy
33,880
+31,417
+1,276% +$528K ﹤0.01% 7209
2023
Q3 		$37.5K Buy
+2,463
New +$33.7K ﹤0.01% 12072
2023
Q2 		– Sell
-21,197
Closed -$230K – 14396
2023
Q1 		$175K Sell
21,197
-51,981
-71% -$487K ﹤0.01% 10395
2022
Q4 		$677K Buy
+73,178
New +$266K ﹤0.01% 7616
2022
Q3 		– Sell
-1,254,479
Closed -$1.51M – 12667
2022
Q2 		$1.33M Sell
1,254,479
-220,621
-15% -$312K ﹤0.01% 6387
2022
Q1 		$2.99M Sell
1,475,100
-24,523
-2% -$64.1K ﹤0.01% 5187
2021
Q4 		$5.68M Buy
1,499,623
+940,156
+168% +$10M ﹤0.01% 4072
2021
Q3 		$6.8M Buy
559,467
+522,135
+1,399% +$4.81M ﹤0.01% 3734
2021
Q2 		$321K Buy
37,332
+18,481
+98% +$182K ﹤0.01% 11103
2021
Q1 		$209K Buy
18,851
+8,042
+74% +$98.2K ﹤0.01% 11600
2020
Q4 		$135K Buy
+10,809
New +$140K ﹤0.01% 10012
2020
Q2 		– Sell
-16,312
Closed -$119K – 9805
2020
Q1 		$119K Buy
+16,312
New +$224K ﹤0.01% 8499

Other funds holding CABA

Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

Citadel Advisors's CABA Position: Q2 2026 in Review

Citadel Advisors opened a new position in Cabaletta Bio (CABA) in Q2 2026: 3,522,112 shares worth $11M. The stake represents ﹤0.01% of the portfolio and ranks #3435 among its holdings. This is a return to the name: Citadel Advisors previously reported a position in CABA as recently as Q4 2025.

Citadel Advisors first reported a position in CABA in Q1 2020 and has held it in 20 quarters since. 139 funds tracked by Wall St. Rank hold CABA as of Q2 2026.

  • Citadel Advisors held 3,522,112 shares of Cabaletta Bio worth $11M as of Q2 2026.
  • Cabaletta Bio was a new Citadel Advisors position in Q2 2026.
  • Cabaletta Bio made up ﹤0.01% of Citadel Advisors's portfolio in Q2 2026, its #3435 holding.
  • Citadel Advisors first reported a position in Cabaletta Bio in Q1 2020 and has held it in 20 quarters since.
  • 139 funds tracked by Wall St. Rank held Cabaletta Bio as of Q2 2026.

Based on Citadel Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.